首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1358082

病毒性結膜炎治療藥物市場：依藥物類別、按病毒類型、按配銷通路、按地區

Viral Conjunctivitis Drugs Market, By Drug Class, By Virus Type (Adenovirus, Enterovirus, Others ), By Distribution Channel, By Geography

出版日期: 2023年08月31日 | 出版商:

Coherent Market Insights | 英文 214 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計2023年，全球病毒性結膜炎治療藥物市值為3.225億美元，預計在預測期內（2023-2030年）年複合成長率為5.1%。

報告範圍		報告詳情
基準年	2022年	2023年市場規模	3.225 億美元
實績資料	2018-2021	預測期	2023-2030
預測期年複合成長率	5.10%	2030年市場規模預測	4.567 億美元

2023 年按藥物類別分類的病毒性結膜炎治療藥物的全球市場佔有率（%）

病毒性結膜炎是由多種病毒引起的急性結膜感染疾病，包括腺病毒和單純皰疹病毒。病毒性結膜炎佔感染性結膜炎的大部分，佔病例的75%。病毒性結膜炎的特徵包括發紅、紅血管、眼睛分泌物、疼痛和畏光。由腺病毒群引起的病毒性結膜炎稱為流行性角結膜炎（EKC）。這群腺病毒有不同的血清型，也可能引起咽結膜熱和特異性濾泡性結膜炎。根據《美國眼科學會：2021》發表的一篇論文，腺病毒性結膜炎是成年人中最常見的眼部感染疾病類型。腺病毒結膜炎具有高度傳染性，引起感染的病毒可以在檯面和其他表面上存活數週。

市場動態

市場參與者正在進行各種無機活動，例如公司收購、產品核可和其他活動，預計這些活動將在預測期內推動全球病毒性結膜炎治療藥物市場的成長。例如，2020 年 2 月，Bausch Health Companies Inc. 和製藥公司的全資子公司 Eton Pharmaceuticals, Inc. 宣布已獲得 Eton Pharmaceuticals 在臨床實驗眼藥水 EM-100 的美國權利。如果核准，該眼藥水將成為第一種用於治療與結膜炎相關的眼睛搔癢的非處方（OTC）不含防腐劑的眼藥水。

此外，2020年7月，全球眼科護理領導者愛爾康宣布，Pataday Once Daily Relief Extra Strength（鹽酸奧洛他定眼用溶液0.7%）（原處方為Pazeo）已獲得美國食品藥物管理局批准，作為過度治療藥物。美國非處方藥（FDA）宣布已獲核准。 Pataday Once Daily Relief Extra Strength 是第一個也是唯一一個每天一次的滴眼液，無需處方箋即可提供 24 小時緩解眼睛瘙癢的效果。過敏是美國慢性病的第六大原因，非處方藥零售額約 27 億美元。

本研究的主要特點

該報告對全球病毒性結膜炎治療藥物市場進行了詳細分析，並提供了以2022年為基準年的預測期（2023-2030年）的市場規模和年複合成長率(CAGR)。它揭示了各個細分市場的潛在商機，並說明了市場有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、抑制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要考察。
它根據公司亮點、產品系列、主要亮點、績效和策略等參數，介紹了全球病毒性結膜炎治療藥物市場的主要企業。
該報告的見解使行銷人員和公司負責人能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的資訊。
全球病毒性結膜炎治療藥物市場報告迎合了該行業的各個相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
相關人員可以透過用於分析全球病毒性結膜炎治療藥物市場的各種策略矩陣來促進決策。

公司簡介
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.mbH
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson &Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.

第10章章

參考
調查方法

簡介目錄

Product Code: CMI1281

The global viral conjunctivitis drugs market is estimated to be valued at US$ 322.5 million in 2023 and is expected to exhibit a CAGR of 5.1% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 322.5 Mn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	5.10%	2030 Value Projection:	US$ 456.7 Mn

Global Viral Conjunctivitis Drugs Market Share (%), By Drug Class, 2023

Viral Conjunctivitis Drugs Market - IMG1

Viral conjunctivitis is an acute conjunctival infection that is caused by various viruses, such adenovirus, herpes simplex virus, etc. Viral conjunctivitis is responsible for the majority of infectious conjunctivitis, accounting for up to 75% of cases. Characteristics of ocular viral conjunctivitis include redness, blood vessel engorgement, ocular discharge, pain, photophobia, etc. Viral conjunctivitis that is caused by a group of adenoviruses is called epidemic keratoconjunctivitis (EKC). This family of adenoviruses contains different serotypes that can cause pharyngoconjunctival fever and nonspecific follicular conjunctivitis as well. According to the article published in the American Academy of Ophthalmology: 2021, adenoviral conjunctivitis is the most common type of eye infection in the adult population. Adenoviral conjunctivitis is highly contagious, as the virus causing the infection can survive on a countertop or a similar surface for several weeks.

Market Dynamics

Market players are engaged in various inorganic activities such as acquisitions of companies, product approval, and others, which in turn is expected to drive growth of the global viral conjunctivitis drugs market over the forecast period. For instance, on February 2020, Bausch Health Companies Inc.'s wholly owned subsidiary, Eton Pharmaceuticals, Inc., a pharmaceutical company, announced that they had acquired the U.S. rights to Eton Pharmaceuticals' EM-100, an investigational eye drop that, if approved, would be the first over-the-counter (OTC) preservative-free formulation eye drop to be used for the treatment of ocular itching associated with conjunctivitis.

Furthermore, in July 2020, Alcon, the global leader in eye care, announced that Pataday Once Daily Relief Extra Strength (olopatadine hydrochloride ophthalmic solution 0.7%), formerly prescribed as Pazeo, had been approved by the U.S. Food and Drug Administration (FDA) for sale over-the-counter (OTC) in the U.S. Pataday Once Daily Relief Extra Strength is the first and only once-daily eye allergy itch drop offering a full 24 hours of relief without a prescription. Allergies are the sixth-leading cause of chronic illness in the U.S., generating approximately US$ 2.7 billion in OTC retail sales.

Key features of the study:

This report provides an in-depth analysis of the global viral conjunctivitis drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global viral conjunctivitis drugs market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include AbbVie Inc., Takeda Pharmaceutical Company Limited, Bausch Health Companies Inc., Panoptes Pharma Ges.m.b.H, NovaBay Pharmaceuticals, Inc., Nicox, NanoViricides Inc., Novartis International AG, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline Plc., Santen Pharmaceutical Co.Ltd., Alcon and Okogen Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global viral conjunctivitis drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral conjunctivitis drugs market.

Detailed Segmentation:

By Drug Class:
- Antibiotics
- Artificial tears
- Decongestants
- Anti-histamines
- NSAIDS
- Anti-Viral drugs
- Others (Steroids, etc.)
By Viral Type:
- Adenovirus
- Enterovirus
- Others (Herpes Simplex Virus (HSV), etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- Bausch Health Companies Inc.
- Panoptes Pharma Ges.m.b.H
- NovaBay Pharmaceuticals, Inc.
- Nicox, NanoViricides Inc.
- Novartis International AG
- Pfizer Inc.
- Johnson & Johnson
- GlaxoSmithKline Plc.
- Santen Pharmaceutical Co.Ltd.
- Alcon
- Okogen Inc.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Virus Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Viral Conjunctivitis Drugs Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Viral Conjunctivitis Drugs Market, By Drug Class, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Artificial tears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Decongestants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Anti-histamines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
NSAIDS
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Anti-Viral drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 -2030, (US$ Mn)
- Segment Trends

6. Global Viral Conjunctivitis Drugs Market, By Virus Type, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Adenovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Enterovirus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
Others (Herpes Simplex Virus (HSV), etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends

7. Global Viral Conjunctivitis Drugs Market, By Distribution Channel, 2018 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)

8. Global Viral Conjunctivitis Drugs Market, By Region, 2018-2030, (US$ Mn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018 -2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018-2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Drug Class, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Virus Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2018-2030, (US$ Mn)
North Africa
Central Africa
South Africa